Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lung Neoplasms 3Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Colorectal Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Melanoma 2Malignant Solid Neoplasm 2Hematopoietic and Lymphatic System Neoplasm 2Carcinoma, Renal Cell 2COVID-19 2Breast Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Spondylitis, Ankylosing 1Renal Insufficiency, Chronic 1Psoriasis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lupus Erythematosus, Systemic 1Localized Head and Neck Carcinoma 1Inflammatory Bowel Diseases 1

Interventions

ixabepilone 1Standard of Care 1Practice Guidelines as Topic 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bilateral Breast Carcinoma × Practice Guidelines as Topic × 30 days × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡